Treatment of Osteoporosis With Anabolic Agents and the Risk of Primary Bone Cancers: A Study of 44,728 Patients Treated With Teriparatide and Abaloparatide.

McDonald CL, Johnson K, Alsoof D, Molino J, Balmaceno-Criss M, Daniels AH

The Journal of the American Academy of Orthopaedic Surgeons10 Mar 2023Cited by 7 (Europe PMC)

PMID36913523DOI10.5435/jaaos-d-22-01094PepBankPUB-36913523

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studySafety outcome
In patients without selected cancer risks, pooled teriparatide or abaloparatide exposure correlated with lower malignancy risk, but incidence rates did not differ significantly.
In plain wordsIn patients without selected cancer risks, pooled teriparatide or abaloparatide use was linked to lower bone cancer risk than nonexposure.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreasePrimary bone malignancy without risk factors
Study
n: not reported in source
Comparator
Matched nonexposed controls
Outcome group
Tumor growth · Cancer
Measurements
Risk
0.02%
exposed
Risk
0.05%
nonexposed
Incidence rate
3.61 per 100,000 person-years
exposed
Incidence rate
6.46 per 100,000 person-years
controls
Risk ratio
0.47 ratio
exposed versus controls
Incidence rate ratio
0.56 ratio
exposed versus controls
Source sentences
Summary
The overall risk of primary bone malignancy development for risk factor-excluded patients in the anabolic agent-exposed group was 0.02%, compared with 0.05% in the nonexposed group. The incidence rate per 100,000 person-years was calculated at 3.61 for the anabolic-exposed patients and 6.46 for control subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
A risk ratio of 0.47 ( P = 0.03) and incidence rate ratio of 0.56 ( P = 0.052) were observed for the development of primary bone malignancies in patients undergoing treatment with bone anabolic agents.
Summary · context
This investigation examined 44,728 patients older than 50 years who were prescribed teriparatide or abaloparatide and compared them with a matched control group to evaluate risk of primary bone cancer development.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3691352301
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In patients without selected cancer risks, pooled teriparatide or abaloparatide exposure correlated with lower malignancy risk, but incidence rates did not differ significantly.
In plain wordsIn patients without selected cancer risks, pooled teriparatide or abaloparatide use was linked to lower bone cancer risk than nonexposure.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePrimary bone malignancy without risk factors
Study
n: not reported in source
Comparator
Matched nonexposed controls
Outcome group
Tumor growth · Cancer
Measurements
Risk
0.02%
exposed
Risk
0.05%
nonexposed
Incidence rate
3.61 per 100,000 person-years
exposed
Incidence rate
6.46 per 100,000 person-years
controls
Risk ratio
0.47 ratio
exposed versus controls
Incidence rate ratio
0.56 ratio
exposed versus controls
Source sentences
Summary
The overall risk of primary bone malignancy development for risk factor-excluded patients in the anabolic agent-exposed group was 0.02%, compared with 0.05% in the nonexposed group. The incidence rate per 100,000 person-years was calculated at 3.61 for the anabolic-exposed patients and 6.46 for control subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
A risk ratio of 0.47 ( P = 0.03) and incidence rate ratio of 0.56 ( P = 0.052) were observed for the development of primary bone malignancies in patients undergoing treatment with bone anabolic agents.
Summary · context
This investigation examined 44,728 patients older than 50 years who were prescribed teriparatide or abaloparatide and compared them with a matched control group to evaluate risk of primary bone cancer development.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3691352302
03HumanNot a test of Abaloparatide (Tymlos) aloneObservational studySafety outcome
In high-risk patients, pooled teriparatide or abaloparatide exposure was linked to lower bone malignancy risk, but incidence rates did not differ significantly.
In plain wordsIn high-risk patients, pooled teriparatide or abaloparatide use was linked to lower cancer risk than nonexposure, with no significant incidence-rate difference.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreasePrimary bone malignancy in high-risk cohort
Study
n: not reported in source
Comparator
Matched nonexposed controls
Outcome group
Tumor growth · Cancer
Measurements
Risk
5.96%
exposed
Risk
8.13%
nonexposed
Risk ratio
0.73 ratio
exposed versus controls
Incidence rate ratio
0.95 ratio
exposed versus controls
Source sentences
Summary
Among high-risk patients, 5.96% of the anabolic-exposed cohort developed primary bone malignancies and 8.13% of nonexposed patients developed primary bone malignancy. The risk ratio was 0.73 ( P = 0.01), and the incidence rate ratio was 0.95 ( P = 0.67).
2 context sentences(design, population, supporting numbers)
Summary · context
A separate cohort of 1,241 patients prescribed an anabolic agent with risk factors of primary bone malignancy, along with 6,199 matched control subjects, was created to evaluate the effect of anabolic agents.
Summary · context
This investigation examined 44,728 patients older than 50 years who were prescribed teriparatide or abaloparatide and compared them with a matched control group to evaluate risk of primary bone cancer development.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3691352303
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In high-risk patients, pooled teriparatide or abaloparatide exposure was linked to lower bone malignancy risk, but incidence rates did not differ significantly.
In plain wordsIn high-risk patients, pooled teriparatide or abaloparatide use was linked to lower cancer risk than nonexposure, with no significant incidence-rate difference.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePrimary bone malignancy in high-risk cohort
Study
n: not reported in source
Comparator
Matched nonexposed controls
Outcome group
Tumor growth · Cancer
Measurements
Risk
5.96%
exposed
Risk
8.13%
nonexposed
Risk ratio
0.73 ratio
exposed versus controls
Incidence rate ratio
0.95 ratio
exposed versus controls
Source sentences
Summary
Among high-risk patients, 5.96% of the anabolic-exposed cohort developed primary bone malignancies and 8.13% of nonexposed patients developed primary bone malignancy. The risk ratio was 0.73 ( P = 0.01), and the incidence rate ratio was 0.95 ( P = 0.67).
2 context sentences(design, population, supporting numbers)
Summary · context
A separate cohort of 1,241 patients prescribed an anabolic agent with risk factors of primary bone malignancy, along with 6,199 matched control subjects, was created to evaluate the effect of anabolic agents.
Summary · context
This investigation examined 44,728 patients older than 50 years who were prescribed teriparatide or abaloparatide and compared them with a matched control group to evaluate risk of primary bone cancer development.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3691352304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.